Apeloa Pharmaceutical
Target ID & ValidationAssay Development & ScreeningHit IdentificationOncologyHematologySmall MoleculePeptide
Quick answer
Aseptic fill-finish is the sterile manufacturing step that fills your purified drug product into vials, syringes, or cartridges and seals them without terminal sterilization. You need it once a formulation is locked, usually from tox supply through Phase 1 onward. BioBridgeX lets buyers source and compare qualified fill-finish CDMOs, free, contracting directly with their chosen supplier.
Aseptic Fill-Finish CDMOs (59)
Famar Group
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentMetabolic / EndocrinologyCardiovascularSmall MoleculeProtein / Enzyme (Recombinant)
Nipro PharmaPackaging
Unclaimed · public records
CDMO · Drug Product Manufacturing, Aseptic Fill-Finish, QC & Release Testing
Drug Product ManufacturingAseptic Fill-FinishQC & Release TestingOncologyInfectious DiseaseSmall MoleculeProtein / Enzyme (Recombinant)
Emergent BioSolutions (CDMO Services)
Unclaimed · public records
CDMO · Process Development, Drug Substance: Biologics, Drug Product Manufacturing
Process DevelopmentDrug Substance: BiologicsDrug Product ManufacturingInfectious DiseaseImmunology & InflammationVaccineMonoclonal Antibody (mAb)
AbbVie Contract Manufacturing
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Drug Substance: Biologics, Formulation Development
Drug Substance: Small Molecule / APIDrug Substance: BiologicsFormulation DevelopmentOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Singota Solutions
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, QC & Release Testing
Aseptic Fill-FinishDrug Product ManufacturingQC & Release TestingOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Symbiosis Pharmaceutical Services
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, QC & Release Testing
Aseptic Fill-FinishDrug Product ManufacturingQC & Release TestingOncologyRare / Orphan DiseaseMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
Novocol Pharma
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentMetabolic / EndocrinologyCNS / NeurologySmall MoleculeProtein / Enzyme (Recombinant)
Lifecore Biomedical
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOphthalmologyOncologySmall MoleculeProtein / Enzyme (Recombinant)
Kindeva Drug Delivery
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentRespiratoryOncologySmall MoleculeProtein / Enzyme (Recombinant)
Grand River Aseptic Manufacturing (GRAM)
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyInfectious DiseaseSmall MoleculeMonoclonal Antibody (mAb)
Curia Global
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Drug Substance: Biologics, Formulation Development
Drug Substance: Small Molecule / APIDrug Substance: BiologicsFormulation DevelopmentOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Jubilant HollisterStier
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyInfectious DiseaseSmall MoleculeProtein / Enzyme (Recombinant)
Siegfried Holding
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Formulation Development, LNP / Delivery Formulation
Drug Substance: Small Molecule / APIFormulation DevelopmentLNP / Delivery FormulationOncologyCNS / NeurologySmall MoleculeProtein / Enzyme (Recombinant)
Aenova Group
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyImmunology & InflammationSmall MoleculeProtein / Enzyme (Recombinant)
Fresenius Kabi Contract Manufacturing
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyInfectious DiseaseSmall MoleculeProtein / Enzyme (Recombinant)
Simtra BioPharma Solutions
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Vetter Pharma
Unclaimed · public records
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Formulation DevelopmentLNP / Delivery FormulationProcess DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
PCI Pharma Services
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, Formulation Development
Aseptic Fill-FinishDrug Product ManufacturingFormulation DevelopmentOncologyImmunology & InflammationAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Formosa Laboratories
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Medicinal & Synthetic Chemistry
ADC / BioconjugationDrug Substance: Small Molecule / APIMedicinal & Synthetic ChemistryOncologyAntibody-Drug Conjugate (ADC)Small Molecule
Pierre Fabre CDMO (Saint-Julien-en-Genevois)
Unclaimed · public records
CDMO · Drug Substance: Biologics, ADC / Bioconjugation, Cell Line / Strain Development
Drug Substance: BiologicsADC / BioconjugationCell Line / Strain DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
BSP Pharmaceuticals
Unclaimed · public records
CDMO · ADC / Bioconjugation, Aseptic Fill-Finish, Drug Product Manufacturing
ADC / BioconjugationAseptic Fill-FinishDrug Product ManufacturingOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Oncotec Pharma Produktion (medac group)
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, Formulation Development
Aseptic Fill-FinishDrug Product ManufacturingFormulation DevelopmentOncologyAntibody-Drug Conjugate (ADC)Small Molecule
CARBOGEN AMCIS
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Medicinal & Synthetic Chemistry
ADC / BioconjugationDrug Substance: Small Molecule / APIMedicinal & Synthetic ChemistryOncologyAntibody-Drug Conjugate (ADC)Small Molecule
MilliporeSigma (SAFC)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Process Development
ADC / BioconjugationDrug Substance: Small Molecule / APIProcess DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
WuXi XDC
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Drug Substance: Small Molecule / API
ADC / BioconjugationDrug Substance: BiologicsDrug Substance: Small Molecule / APIOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
MabPlex
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Cell Line / Strain Development
ADC / BioconjugationDrug Substance: BiologicsCell Line / Strain DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Recipharm
Unclaimed · public records
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Drug Product Manufacturing
mRNA / RNA ManufacturingLNP / Delivery FormulationDrug Product ManufacturingInfectious DiseaseOncologymRNA / saRNASmall Molecule
Ascendia Pharmaceutical Solutions
Unclaimed · public records
CDMO · LNP / Delivery Formulation, Formulation Development, Drug Product Manufacturing
LNP / Delivery FormulationFormulation DevelopmentDrug Product ManufacturingOncologyCNS / NeurologymRNA / saRNASmall Molecule
Merck Millipore (MilliporeSigma / Sigma-Aldrich CTDMO)
Unclaimed · public records
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Plasmid DNA Manufacturing
mRNA / RNA ManufacturingLNP / Delivery FormulationPlasmid DNA ManufacturingOncologyInfectious DiseasemRNA / saRNAPlasmid DNA
Fujifilm (Toyama Chemical / FUJIFILM Diosynth LNP)
Unclaimed · public records
CDMO · mRNA / RNA Manufacturing, LNP / Delivery Formulation, Aseptic Fill-Finish
mRNA / RNA ManufacturingLNP / Delivery FormulationAseptic Fill-FinishInfectious DiseaseOncologymRNA / saRNAVaccine
Ajinomoto Bio-Pharma Services
Unclaimed · public records
CRO & CDMO · Peptide / Oligo Synthesis, ADC / Bioconjugation, Drug Substance: Small Molecule / API
Peptide / Oligo SynthesisADC / BioconjugationDrug Substance: Small Molecule / APIOncologyMetabolic / EndocrinologyPeptideOligonucleotide (ASO / siRNA)
Polymun Scientific
Unclaimed · public records
CDMO · LNP / Delivery Formulation, mRNA / RNA Manufacturing, Formulation Development
LNP / Delivery FormulationmRNA / RNA ManufacturingFormulation DevelopmentInfectious DiseaseOncologymRNA / saRNAVaccine
IDT Biologika
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Process Development, Analytical Development
Viral Vector ManufacturingProcess DevelopmentAnalytical DevelopmentInfectious DiseaseOncologyGene Therapy (AAV / Viral Vector)Vaccine
Vibalogics (ReciBioPharm / Recipharm)
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Process Development, Analytical Development
Viral Vector ManufacturingProcess DevelopmentAnalytical DevelopmentOncologyInfectious DiseaseGene Therapy (AAV / Viral Vector)Vaccine
Esco Aster
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyInfectious DiseaseGene Therapy (AAV / Viral Vector)Plasmid DNA
3PBIOVIAN (3P Biopharmaceuticals + Biovian)
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyRare / Orphan DiseaseGene Therapy (AAV / Viral Vector)Plasmid DNA
PackGene Biotech
Unclaimed · public records
CRO & CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, mRNA / RNA Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingmRNA / RNA ManufacturingOncologyRare / Orphan DiseaseGene Therapy (AAV / Viral Vector)mRNA / saRNA
Aldevron (Danaher)
Unclaimed · public records
CDMO · Plasmid DNA Manufacturing, mRNA / RNA Manufacturing, Process Development
Plasmid DNA ManufacturingmRNA / RNA ManufacturingProcess DevelopmentOncologyHematologyPlasmid DNAmRNA / saRNA
National Resilience
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, mRNA / RNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingmRNA / RNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
FUJIFILM Biotechnologies (formerly FUJIFILM Diosynth)
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Process Development
Viral Vector ManufacturingCell Therapy ManufacturingProcess DevelopmentOncologyRare / Orphan DiseaseGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Catalent
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Wacker Biotech
Unclaimed · public records
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Process DevelopmentAnalytical DevelopmentDrug Substance: BiologicsInfectious DiseaseImmunology & InflammationProtein / Enzyme (Recombinant)Vaccine
3PBIOVIAN
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
GBI (Goodwin Biotechnology)
Unclaimed · public records
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Process DevelopmentAnalytical DevelopmentDrug Substance: BiologicsOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
Northway Biotech
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
Catalent Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Boehringer Ingelheim BioXcellence
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
WuXi Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Samsung Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Curia (formerly AMRI)
Unclaimed · public records
CRO & CDMO · Target ID & Validation, Hit-to-Lead, Lead Optimization
Target ID & ValidationHit-to-LeadLead OptimizationOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Pfizer CentreOne
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentInfectious DiseaseOncologySmall MoleculeMonoclonal Antibody (mAb)
Thermo Fisher Scientific (Patheon)
Unclaimed · public records
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Process DevelopmentDrug Substance: Small Molecule / APIAnalytical DevelopmentOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Dr. Reddy's Custom Pharma Services (CPS)
Unclaimed · public records
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Process DevelopmentDrug Substance: Small Molecule / APIAnalytical DevelopmentOncologyCardiovascularSmall MoleculePeptide
Piramal Pharma Solutions
Unclaimed · public records
CRO & CDMO · Hit-to-Lead, Lead Optimization, Medicinal & Synthetic Chemistry
Hit-to-LeadLead OptimizationMedicinal & Synthetic ChemistryOncologyCNS / NeurologySmall MoleculeAntibody-Drug Conjugate (ADC)
Fareva
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyInfectious DiseaseSmall MoleculeProtein / Enzyme (Recombinant)
CordenPharma
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyMetabolic / EndocrinologySmall MoleculePeptide
Siegfried
Unclaimed · public records
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyCNS / NeurologySmall Molecule
Lonza
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyRare / Orphan DiseaseSmall MoleculeAntibody-Drug Conjugate (ADC)
What is aseptic fill-finish and when do you need it?
Aseptic fill-finish is the last step in making a sterile drug product. After your bulk drug substance has been formulated and filtered, a fill-finish line meters it into the final container (a vial, a prefilled syringe, a cartridge, or a cartridge that later goes into a pen or autoinjector), stoppers it, and seals it. Because most biologics and many small molecules cannot survive terminal sterilization in an autoclave, the whole operation runs under aseptic conditions: Grade A air over the fill point, sterile-filtered product, sterilized components, and operators who almost never touch the open container. If a unit is compromised at this step, there is no rescue downstream, which is why FDA and EMA scrutiny on sterility assurance is heavier here than almost anywhere else in CMC.
You typically need a fill-finish partner once your formulation is locked and you are producing material for GLP tox, a first-in-human study, or any clinical phase. For an injectable program the practical trigger is your Phase 1 batch: you have drug substance, you have a formulation that holds up in early stability, and now you need filled, labeled, sterile units with a real batch record behind them. Some sponsors fill at the same CDMO that made the drug substance; many split drug substance and drug product across two sites, which then forces a tech transfer and a comparability conversation. Programs that include lyophilization (freeze-drying) need to size that in early, because lyo cycle development and chamber capacity drive both cost and lead time.
The container and presentation decision usually drives the whole sourcing exercise. A 2 mL liquid vial filled on a flexible line is a very different job from a prefilled syringe with siliconization control, or a lyophilized vial that needs a validated freeze-drying cycle, or a high-potency or cytotoxic product that demands isolator containment. Match the presentation, the batch size, and the modality first, then shortlist CDMOs that actually run that configuration at the scale you need rather than the one they would prefer to sell you.
What does an aseptic fill-finish CDMO actually do?
A fill-finish CDMO takes your formulated bulk and turns it into released, sterile final product. In practice that means receiving and testing your drug substance, sterile-filtering the formulation, filling into the chosen container under Grade A conditions, stoppering and capping, and, where required, running a lyophilization cycle. Around the fill they handle component preparation (washing, depyrogenation, and sterilization of vials and stoppers), environmental monitoring, in-process checks such as fill-weight and container-closure integrity, and 100% or statistical inspection for particulates and cosmetic defects. Many also offer secondary work like labeling, kitting, and serialization, or hand that to a separate packaging partner.
Before they fill a single commercial-intent batch, a credible CDMO runs aseptic process simulations (media fills) to qualify the line and the operators, and they will expect to repeat them on a defined cadence. Expect them to own or co-own container-closure integrity testing (CCIT), extractables and leachables strategy on the container system, and the sterility and endotoxin release testing, either in-house or through a qualified lab. For programs heading toward filing, the CDMO contributes the drug-product manufacturing section of your CMC package and supports process validation. The strongest partners are honest early about what they cannot do, for example isolator capacity for a cytotoxic product or a particular syringe format, rather than letting you discover the gap during tech transfer.
How to choose an aseptic fill-finish CDMO?
The container, the batch size, and the modality narrow the field fast, and from there the decision is mostly about sterility assurance track record, available capacity in your window, and how clean their inspection history is. Use the checklist below to compare CDMOs on the things that actually decide a program, then source and shortlist qualified suppliers against your specific presentation rather than a generic capability list.
- Quality and GxP status: current GMP certification, recent FDA / EMA inspection history (483 observations and how they were closed), media fill results, and a sterility assurance program you can audit.
- Capacity and lead time: realistic line availability in your window, clinical versus commercial scale, lyophilization chamber capacity if you need it, and honest changeover and slot-booking timelines, not best-case quotes.
- Modality and presentation fit: experience with your exact format (liquid vial, lyo vial, prefilled syringe, cartridge) and modality (mAb, peptide, ADC or cytotoxic, cell or gene therapy, vaccine), including isolator containment where the product demands it.
- Region and regulatory track record: where the site sits relative to your filing markets, a clean inspection record with the agencies you will file with, and demonstrated experience supporting comparable BLA, NDA, or clinical submissions.
- Data quality and documentation: clean batch records, full environmental monitoring and in-process data, container-closure integrity and particulate inspection results, and a CMC dossier contribution you can drop into your regulatory package.
- IP and confidentiality: a clear CDA before disclosure, defined ownership of process know-how and any improvements, segregation from competitor programs, and named, qualified subcontractors for testing or lyo work.
Frequently asked questions
What is the difference between aseptic fill-finish and terminal sterilization?
Terminal sterilization sterilizes the product after it is sealed in its final container, usually with heat or radiation, so the whole sealed unit is treated at once. Aseptic fill-finish keeps everything sterile throughout the fill instead: the product is sterile-filtered, the components are pre-sterilized, and filling happens under Grade A conditions, because most biologics and many sensitive small molecules would be degraded by terminal heat or radiation. Aseptic processing carries a higher sterility-assurance burden, which is why media fills, environmental monitoring, and container-closure integrity testing matter so much.
Should I use the same CDMO for drug substance and drug product?
Both models are common. A single site for drug substance and fill-finish removes one tech transfer, simplifies your supply chain, and can shorten timelines. Splitting them lets you pick the best specialist for each step, for example a dedicated sterile fill site with the exact syringe line or isolator you need, but it adds a tech transfer of the formulated bulk and a comparability conversation. Decide based on whether one site genuinely does both well at your scale, and weigh the schedule and the added quality oversight of running two sites.
What does aseptic fill-finish typically cost and how long does it take?
Cost and lead time depend heavily on container format, batch size, whether lyophilization is involved, and how busy the line is, so any single number is misleading. The bigger schedule driver is usually slot availability rather than the fill itself: booking a line, completing tech transfer, running an engineering or media-fill batch, and releasing the lot all add weeks. Treat a CDMO's quoted timeline as best-case, ask specifically about line availability in your window and lyo chamber capacity, and build in buffer for stability and release testing.
What sterility and quality testing happens during fill-finish?
Expect aseptic process simulations (media fills) to qualify the line and operators, plus environmental monitoring throughout the fill. Per-batch testing typically includes sterility, bacterial endotoxin, container-closure integrity (CCIT), particulate and visual inspection, fill-weight or volume checks, and the relevant product-specific release assays. For the container system you will also need an extractables and leachables strategy. Confirm which tests the CDMO runs in-house versus through a qualified subcontractor, and make sure the data is clean enough to drop straight into your regulatory dossier.
Can a fill-finish CDMO handle high-potency, cytotoxic, or cell and gene therapy products?
Some can, but it is the single most common capability gap, so confirm it before shortlisting. High-potency and cytotoxic products (including many ADCs) require isolator-based containment and dedicated handling, and not every site has the isolator capacity free. Cell and gene therapies bring cold-chain, small-batch, and single-use considerations that many traditional vial lines are not set up for. Ask directly about containment level, the exact presentation, and recent experience with your modality rather than assuming a general sterile-fill capability covers it.
How does sourcing fill-finish CDMOs through BioBridgeX work?
BioBridgeX is a neutral marketplace, free for buyers. You describe your program (container format, modality, batch size, lyo needs, target markets) and get matched with qualified fill-finish CDMOs, so you can compare them side by side instead of cold-emailing sites one at a time. If you engage more than one supplier, you contract once and receive a single PO and invoice across them, with a flat 2% fee paid by the supplier, not the buyer. The platform is modality- and indication-agnostic.
Source Aseptic Fill-Finish with one contract
Compare transparent quotes from qualified Aseptic Fill-Finish CDMOs, then contract once. Free for buyers.
Compare quotes